Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2020;31(4):427-9
Article Links
The Role of Novel Autoantibodies in the Diagnostic Approach and Prognosis of Patients with Raynaud’s Phenomenon
Vasiliki Koulouri1, Adrianos Nezos1, Nikolaos Marketos1,2, Evangelia Argyriou1,3, Kyriaki Boki3, Dimitrios Ioakimidis2, Michalis Koutsilieris1, Clio P. Mavragani1,4
Authors Information

1. Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

2. Rheumatology Outpatient Department, Henry Dunant Hospital Centre, Athens, Greece

3. Rheumatology Unit, Sismanogleio General Hospital, Athens, Greece

4. Rheumatology Outpatient Unit, Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece

Vasiliki Koulouri, Adrianos Nezos, Nikolaos Marketos, Kyriaki Boki

Keywords: Autoantibodies, Raynaud’s phenomenon, systemic autoimmune rheumatic disease
References
  1. Belch J, Carlizza A, Carpentier PH, Constans J, Khan F, Wautrecht JC, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa 2017;46:413-23.
  2. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012;71:1355-60.
  3. De Angelis R, Cerioni A, Del Medico P, Blasetti P. Raynaud's phenomenon in undifferentiated connective tissue disease (UCTD). Clin Rheumatol 2005;24:145-51.
  4. Grader-Beck T, Wigley FM. Raynaud's phenomenon in mixed connective tissue disease. Rheum Dis Clin North Am 2005;31:465-81, vi.
  5. Heimovski FE, Simioni JA, Skare TL: Systemic lupus erythematosus and Raynaud's phenomenon. An Bras Dermatol 2015;90:837-40.
  6. Garcia-Carrasco M, Siso A, Ramos-Casals M, Rosas J, de la Red G, Gil V, et al. Raynaud's phenomenon in primary Sjogren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 2002;29:726-30.
  7. Skopouli FN, Talal A, Galanopoulou V, Tsampoulas CG, Drosos AA, Moutsopoulos HM. Raynaud's phenomenon in primary Sjogren's syndrome. J Rheumatol 1990, 17:618-20.
  8. Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001;357:2042-8.
  9. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998;158:595-600.
  10. Didier K, Bolko L, Giusti D, Toquet S, Robbins A, Antonicelli F, et al. Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians? Front Immunol 2018;9:541.
  11. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58:3902-12.
  12. Schlager O, Kiener HP, Stein L, Hofkirchner J, Zehetmayer S, Ristl R, et al. Associations of nailfold capillary abnormalities and immunological markers in early Raynaud's phenomenon. Scand J Rheumatol 2014;43:226-33.
  13. Mueller M, Gschwandtner ME, Gamper J, Giurgea GA, Charwat-Resl S, Kiener HP, et al. Relation of Nailfold Capillaries and Autoantibodies to Mortality in Patients With Raynaud Phenomenon. Circulation 2016;133:509-17.
  14. Falcini F, Rigante D, Candelli M, Martini G, Corona F, Petaccia A, et al. Anti-nuclear antibodies as predictor of outcome in a multi-center cohort of Italian children and adolescents with Raynaud's phenomenon. Clin Rheumatol 2015;34:167-9.
  15. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 2010;138:1464-74.
  16. Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 2011;37:100-9.
  17. Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012;11:739-45.
  18. Zampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, et al. Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clin Rheumatol 2019;38:125-32.
  19. Amigues JM, Cantagrel A, Abbal M, Mazieres B. Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol 1996;23:2055-62.
  20. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003;42:534-40.
  21. To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 2005;52:4003-10.
  22. Nakano M, Hasegawa H, Takada T, Ito S, Muramatsu Y, Satoh M, et al. Pulmonary diffusion capacity in patients with systemic lupus erythematosus. Respirology 2002;7:45-9.
  23. Jordan S, Maurer B, Toniolo M, Michel B, Distler O. Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. Rheumatology (Oxford) 2015;54:1454-8.
  24. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011;70:476-81.
  25. Lepri G, Guiducci S, Bellando-Randone S, Giani I, Bruni C, Blagojevic J, et al. Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. Ann Rheum Dis 2015;74:124-8.